DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness ...

Dexcom’s first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be ...

The nomination criteria used by the selection committee are focused on seeking college athletes with diabetes who are passionate about sharing their inspirational stories with others to serve as ...

--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated ... of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

Tom Hanks revealed his type 2 diabetes diagnosis in 2013 after years of ignoring high blood sugar levels. He blamed weight gain and unhealthy habits, calling himself a "total idiot" for not taking ...

Updated recommendations from an international group of diabetes experts aim to inform diabetes educators about best practices ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Scientists have identified a simple, noninvasive method for assessing blood glucose regulation using continuous glucose monitoring (CGM) data. Their approach, which tracks glucose fluctuations, ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.